MedTrace Logo

Treatment Study of Carnosine Versus Placebo in Gulf War Illness (GWI)

NCT00810368 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2019-06-28

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to perform a randomized double-blind, placebo-controlled, 12 week study of the effects of carnosine on cognitive, psychometric, autonomic, and muscle strength outcomes in 100 GWI subjects.

Conditions

  • Persian Gulf Syndrome

Interventions

DRUG

Carnosine

500mg Carnosine x2 daily

DRUG

Placebo

Microcrystalline cellulose placebo tablets x2 daily

Sponsors & Collaborators

  • Georgetown University

    lead OTHER

Principal Investigators

  • James N Baraniuk, MD · Georgetown University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
34 Years
Max Age
82 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-08-31
Primary Completion
2012-07-31
Completion
2012-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00810368 on ClinicalTrials.gov